Iovance Biotherapeutics, Inc. (IOVA)
8.07
-0.22
(-2.65%)
USD |
NASDAQ |
Aug 24, 16:00
8.05
-0.02
(-0.25%)
After-Hours: 20:00
Iovance Biotherapeutics EPS Diluted (Quarterly) : -0.1051 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1051 |
| March 31, 2026 | -0.1889 |
| December 31, 2025 | -0.1767 |
| September 30, 2025 | -0.2507 |
| June 30, 2025 | -0.3338 |
| March 31, 2025 | -0.3598 |
| December 31, 2024 | -0.2577 |
| September 30, 2024 | -0.2755 |
| June 30, 2024 | -0.3409 |
| March 31, 2024 | -0.4244 |
| December 31, 2023 | -0.4547 |
| September 30, 2023 | -0.4628 |
| June 30, 2023 | -0.4746 |
| March 31, 2023 | -0.5024 |
| December 31, 2022 | -0.6392 |
| September 30, 2022 | -0.6312 |
| June 30, 2022 | -0.6317 |
| March 31, 2022 | -0.5831 |
| December 31, 2021 | -0.633 |
| September 30, 2021 | -0.5538 |
| June 30, 2021 | -0.5291 |
| March 31, 2021 | -0.512 |
| December 31, 2020 | -0.4661 |
| September 30, 2020 | -0.3998 |
| June 30, 2020 | -0.4732 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.5499 |
| December 31, 2019 | -0.5034 |
| September 30, 2019 | -0.399 |
| June 30, 2019 | -0.3848 |
| March 31, 2019 | -0.2994 |
| December 31, 2018 | -0.2735 |
| September 30, 2018 | -0.3558 |
| June 30, 2018 | -0.34 |
| March 31, 2018 | -0.3143 |
| December 31, 2017 | -0.36 |
| September 30, 2017 | -0.35 |
| June 30, 2017 | -0.37 |
| March 31, 2017 | -0.33 |
| December 31, 2016 | -0.25 |
| September 30, 2016 | -1.15 |
| June 30, 2016 | -0.23 |
| March 31, 2016 | -0.14 |
| December 31, 2015 | -0.20 |
| September 30, 2015 | -0.16 |
| June 30, 2015 | -0.14 |
| March 31, 2015 | -0.14 |
| December 31, 2014 | -0.1442 |
| September 30, 2014 | -0.11 |
| June 30, 2014 | -0.09 |
| March 31, 2014 | -0.11 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 4.366 |
| Neurocrine Biosciences, Inc. | 1.386 |
| Anika Therapeutics, Inc. | 0.2412 |
| BioCryst Pharmaceuticals, Inc. | 0.2957 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -47.32M |
| Revenue (Quarterly) | 99.31M |
| Total Expenses (Quarterly) | 146.63M |
| Enterprise Value | 3.503B |
| Gross Profit Margin (Quarterly) | 46.54% |
| Profit Margin (Quarterly) | -47.64% |
| Earnings Yield | -8.94% |
| Normalized Earnings Yield | -8.815 |